Market Place
Sourcing Support
GSK’s Omjjara Receives Japanese Approval For Myelofibrosis Treatment
25 Jun 2024 //
PHARMABIZ
European Commission authorises GSK’s Omjjara (momelotinib)
29 Jan 2024 //
PRESS RELEASE
OJJAARA™ (momelotinib) Now Available from Onco360 For MF
25 Sep 2023 //
BUSINESSWIRE
US FDA approves GSK`s bone marrow cancer therapy
16 Sep 2023 //
REUTERS
Combination Therapies May Spur Evolution of the Myelofibrosis Treatment Paradigm
22 Jun 2023 //
ONCLIVE
FDA delays approval decision on GSK`s $1.9B blood cancer bet
17 Jun 2023 //
FIERCE BIOTECH
New data at ASH underscore the potential for durable responses with momelotinib
11 Dec 2022 //
BUSINESSWIRE
ASH: GSK explores new avenues for JAK drug from $1.9B Sierra buy
11 Dec 2022 //
FIERCEBIOTECH
EMA accepts momelotinib marketing application
05 Dec 2022 //
EUROPEANPHARMACEUTICALREVIEW
GSK’s two new cancer drugs look promising
03 Dec 2022 //
PHARMAFILE
GSK’s new drug application for momelotinib accepted by FDA
18 Aug 2022 //
PHARMAFILE
US FDA accepts GSK`s new drug application for momelotinib
17 Aug 2022 //
ISE UK
Sierra Oncology Announces Submission of NDA for Momelotinib to FDA
17 Jun 2022 //
BUSINESSWIRE
Momelotinib Pivotal Phase 3 Data Receives Oral Presentation at ASCO
26 May 2022 //
BUSINESSWIRE
GSK inks $2B Sierra takeover, turning $3M bet into big buyout
14 Apr 2022 //
FIERCEBIOTECH
Sierra Oncology Announces Closing of Upsized Public Offering of $135M
31 Jan 2022 //
BUSINESSWIRE
Sierra’s bet on Gilead castoff pays off, teeing up FDA filing
26 Jan 2022 //
FIERCEBIOTECH
Sierra Oncology records success in late-stage study of bone cancer drug
25 Jan 2022 //
BIOPHARMADIVE
Momelotinib Review Article Published in Journal of Hematology & Oncology
19 Jan 2022 //
BUSINESSWIRE
Sierra Oncology Updates Topline Data Timing for Phase 3 Trial of Momelotinib
18 Jan 2022 //
BUSINESSWIRE
Sierra Oncology to Report Momelotinib Long-term Overall Survival Data
05 Nov 2020 //
PRNEWSWIRE
Sierra Oncology Strengthens Management Team to Implement N American Momelotinib
06 Aug 2020 //
PRNEWSWIRE
Sierra Oncology Reports Favorable Long-Term Safety for Momelotinib
11 Jun 2020 //
PRNEWSWIRE
Sierra Oncology brings on former Aimmune CEO to the helm
30 May 2020 //
ENDPTS
Sierra Oncology brings on former Aimmune CEO to the helm; Flagship
29 May 2020 //
ENDPTS
Meet the protein responsible for nearly $100B in cancer drug deals
17 Aug 2019 //
BIOPHARMADIVE
Sierra doubles down on ex-Gilead drug, deprioritizes other assets
28 Jun 2019 //
FIERCE BIOTECH
Gilead paid $510M for drug and just sold it for $3 million
24 Aug 2018 //
CNBC
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.